Plasma prostaglandins in lung cancer.
Plasma levels of three stable prostaglandin (PG) metabolites were measured in 29 patients with lung cancer. The mean level of 6-keto-PGF1 alpha, the hydrolysis product of prostacyclin, was significantly elevated in cancer patients compared to a control group with non-malignant respiratory disorders, although an overlap in values between the groups was seen. Levels correlated inversely with survival and showed a significant fall in 14 patients with tumour regression. The mean level of 11-deoxy-3,14-dihydro-15-keto-11,16-cyclo-prostaglandin E2 was also significantly elevated in cancer patients, but did not correlate with tumour response. 13,14-Dihydro-15-keto prostaglandin F2 alpha levels did not differ in lung cancer patients and controls. Contrary to previous reports we could not support a role for the metabolites of PGE2 and PGF2 alpha as tumour markers in lung cancer but plasma 6-keto-PGF1 alpha should be further evaluated in this regard.
Hendrick
A M
AM
Department of Clinical Oncology, University of Newcastle upon Tyne, U.K.
Mitchell
M D
MD
Harris
A L
AL
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood; D015237:Dinoprost / Q000031:analogs & derivatives*; D015232:Dinoprostone / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011453:Prostaglandins / Q000097:blood*; D011458:Prostaglandins E / Q000097:blood; D011460:Prostaglandins F / Q000097:blood
D014408:Biomarkers, Tumor; D011453:Prostaglandins; D011458:Prostaglandins E; D011460:Prostaglandins F; C008228:15-keto-13,14-dihydroprostaglandin F2alpha; D015121:6-Ketoprostaglandin F1 alpha; C025088:11-deoxy-15-keto-13,14-dihydro-11 beta,16-cycloprostaglandin E2; D015237:Dinoprost; D015232:Dinoprostone